Many human medications can directly inhibit the growth and alter the function of the bacteria that constitute our gut microbiome.
Biotech’s 2024 IPO season kicks off with heavy demand for CG Oncology in $380M listing
NEW YORK — Bladder cancer drugmaker CG Oncology will debut on Nasdaq Thursday morning in what is expected to be the first of at least